Osilodrostat blocks cortisol synthesis and may increase circulating levels of cortisol and aldosterone precursors (11-deoxy cortisol and 11-deoxycorticosterone) and androgens. Hypertension and hypokalemia were the most common adrenal hormone precursor-related adverse reactions observed in clinical trials.
- TRADE NAME: Isturisa (Novartis)
- INDICATIONS: Treatment of adult patients with Cushing’s disease
- CLASS: Cortisol synthesis inhibitor
- HALF-LIFE: ~ 4 hours
- FDA APPROVAL DATE: 03/06/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clarithromycin, CYP3A4 inhibitors, CYP3A4 inducers, CYP2B6 inducers, Itraconazole, Phenobarbital, Phenobarbital, Rifampin - PREGNANCY: No available data in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
